| Naslov: | Temocillin : a narrative review of its clinical reappraisal |
|---|
| Avtorji: | ID Cosimi, Lavinia (Avtor)
ID Zerbato, Verena (Avtor)
ID Grasselli Kmet, Nina (Avtor)
ID Oliva, Alessandra (Avtor)
ID Cogliati Dezza, Francesco (Avtor)
ID Nadrah, Kristina (Avtor)
ID Pirš, Mateja (Avtor)
ID Saletinger, Rajko (Avtor), et al. |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (743,84 KB)
MD5: B4451F29857C0B783441BAD83DF0BAF8
 URL - Izvorni URL, za dostop obiščite https://doi.org/10.3390/antibiotics14090859
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Background: The emergence of multidrug-resistant Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL) and AmpC-producing Enterobacterales, has brought renewed interest in temocillin, a narrow-spectrum β-lactam antibiotic first introduced in the 1980s. Objectives: We aimed to provide a comprehensive overview of the microbiological, pharmacological, and clinical profile of temocillin. Methods: We conducted a narrative review of the literature using the PubMed database to identify relevant studies concerning the microbiology, pharmacokinetics, pharmacodynamics, clinical applications, and safety of temocillin. Results: Temocillin shows strong in vitro activity against ESBL- and AmpC-producing organisms, and partial efficacy against certain Klebsiella pneumoniae carbapenemase (KPC)-producing strains. Its pharmacokinetic and pharmacodynamic characteristics, including β-lactamase stability and low ecological impact, support its use in urinary tract infections, bloodstream infections, intra-abdominal infections, pneumonia, and central nervous system infections. Additionally, evidence supports its utility in outpatient parenteral antimicrobial therapy (OPAT), including subcutaneous administration, and in vulnerable populations such as pediatric, elderly, and immunocompromised patients. Temocillin demonstrates a favorable safety profile, minimal disruption of gut microbiota, and cost-effectiveness. It also exhibits synergistic activity with agents like fosfomycin, further enhancing its clinical value. Most of the current evidence is derived from retrospective and observational studies. Conclusions: Temocillin emerges as a promising carbapenem-sparing option for the treatment of challenging infections caused by multidrug-resistant Gram-negative bacteria. |
|---|
| Ključne besede: | temocillin, extended-spectrum β-lactamase, AmpC, Klebsiella pneumoniae carbapenemase, carbapenem-sparing, antimicrobial stewardship, outpatient parenteral antimicrobial therapy, Enterobacterales |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 1-19 |
|---|
| Številčenje: | Vol. 14, iss. 9, [article no.] 859 |
|---|
| PID: | 20.500.12556/DiRROS-27738  |
|---|
| UDK: | 615.33 |
|---|
| ISSN pri članku: | 2079-6382 |
|---|
| DOI: | 10.3390/antibiotics14090859 |
|---|
| COBISS.SI-ID: | 246894595 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 28. 8. 2025;
|
|---|
| Datum objave v DiRROS: | 23.02.2026 |
|---|
| Število ogledov: | 32 |
|---|
| Število prenosov: | 16 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
